Devers Shannon L.

SEC source: 0000874015-25-000058 · edgardoc.xml · nonDerivative · entry 2

Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,937

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.76 to $32.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000058 · edgardoc.xml · derivative · entry 5

Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,226

Underlying: Common Stock · 12,295 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000058 · edgardoc.xml · derivative · entry 4

Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,521

Underlying: Common Stock · 33,000 shares

Expires not disclosed

F6 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000058 · edgardoc.xml · derivative · entry 3

Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires not disclosed

F4 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F5 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F5 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-25-000058 · edgardoc.xml · nonDerivative · entry 1

Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-25-000018 · edgardoc.xml · derivative · entry 1

Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: Grant on 01/02/2025 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2025. 25% of the shares subject to the option will vest and become exercisable on 01/02/2026. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000228 · edgardoc.xml · derivative · entry 1

Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,521

Underlying: Common Stock · 11,280 shares

Expires not disclosed

F1 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000225 · edgardoc.xml · derivative · entry 1

Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resourses Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,040

Underlying: Common Stock · 15,040 shares

Expires 2034-09-28

F1 · derivative.exercise_date: Grant on 09/29/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 09/29/2024. 25% of the shares subject to the option will vest and become exercisable on 09/29/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.